Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Specification of haematopoetic stem cell fate via modulation of mitochondrial activity

Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland
Specification of haematopoetic stem cell fate via modulation of mitochondrial activity ( Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland )
17 Jun 2018

Onset and treatment of infantile leukaemia

Dr Anindita Roy - University of Oxford, Oxford, UK
Onset and treatment of infantile leukaemia ( Dr Anindita Roy - University of Oxford, Oxford, UK )
17 Jun 2018

Editor’s Choice for May 2018

Prof Gordon McVie - Founding Editor, ecancer
Editor’s Choice for May 2018 ( Prof Gordon McVie - Founding Editor, ecancer )
21 May 2018

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA
Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )
25 Apr 2018

Phase I taselisib results and a cell-free DNA assay

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA
Phase I taselisib results and a cell-free DNA assay ( Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )
25 Apr 2018

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA
Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )
25 Apr 2018

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK
A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )
25 Apr 2018

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK
Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )
25 Apr 2018

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK
Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )
25 Apr 2018

Clinical development and economic prospects of CAR T cell immunotherapies

Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA
Clinical development and economic prospects of CAR T cell immunotherapies ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )
25 Apr 2018

The best sequence of anti-HER2 therapy in metastatic breast cancer

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain
The best sequence of anti-HER2 therapy in metastatic breast cancer ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )
29 Jan 2018

ESO-ESMO-ABC guidelines in metastatic breast cancer

Dr Nagi El Saghir - American University of Beirut, Beirut, Lebanon
ESO-ESMO-ABC guidelines in metastatic breast cancer ( Dr Nagi El Saghir - American University of Beirut, Beirut, Lebanon )
26 Jan 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation